LOS ANGELES, CA / ACCESSWIRE / July 5,2017 / Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against Akari Therapeutics, Plc ("Akari" or the "Company") (NASDAQ: AKTX) for possible violations of federal securities laws from March 30, 2017 through May 11, 2017 inclusive (the "Class Period"). Investors who purchased or otherwise acquired Akari shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at email@example.com.
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may choose to do nothing and be an absent class member as well.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called "Akari's Coversin matches Soliris in Phase II." The next day it was announced that the report was withdrawn because of "material inaccuracies." On May 11, 2017, Akari announced that Chief Executive Officer Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. Upon the release of this information, Akari shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, Esq., a securities litigator based in Los Angeles dedicated to upholding shareholders' rights.
This press release may constitute Attorney Advertising in certain jurisdictions under the applicable law and rules of ethics.
Lundin Law PC
Brian Lundin, Esq.
SOURCE: Lundin Law PC